CHS-3318 / Coherus Oncology - LARVOL DELTA

Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event (GlobeNewswire) - "CHS-006 (anti-TIGIT antibody) is being evaluated in an ongoing clinical trial. In 2023, Coherus expects to receive clinical data informing dose-selection and is planning to enroll new patient cohorts in the United States to evaluate CHS-006 + toripalimab for treatment of several solid tumor indications that may include non-small cell lung cancer, small cell lung cancer, esophageal cancer, and hepatocellular carcinoma....Coherus expects to file investigational new drug ('IND') applications with the FDA in 2023 for CHS-1000, an antibody targeting ILT4, and in 2024 for CHS-3318, an antibody targeting CCR8....Toripalimab launch readiness is on track and will benefit from the high overlap in customer accounts between UDENYCA® and toripalimab. If approved, toripalimab will be the first and only PD-1 inhibitor registered in the United States for the treatment of advanced nasopharyngeal carcinoma."

Clinical data • Enrollment status • IND • Esophageal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor